With upcoming phase III trials and the expected approval of next-generation inhibitors, the future landscape might be set and HIF-2α -inhibition might find its place as another mainstay in the treatment of ccRCC. This evidence concerns the gene EPAS1 and nonpapillary renal cell carcinoma.